Abstract
Drug abuse treatment programs in six regions of the United States collaborated in a study aimed at monitoring trends in the seroprevalence of human immunodeficiency virus (HIV) antibodies. The wide disparities in HIV seroprevalence in the face of similarities in drug using behavior have important implications for prevention. In the New York City area (Harlem, Brooklyn), 61 per cent of samples (N = 280) obtained in late 1986 were positive, up from 50 per cent of samples (N = 585) in early 1985. In Baltimore, Maryland, 29 per cent of samples (N = 184) representing 11 programs were positive. In contrast, samples from programs distant from the Northeast corridor had far lower rates: Denver, Colorado 5 per cent (N = 100); San Antonio, Texas 2 per cent (N = 106); Southern California, 1.5 per cent (N = 413); and Tampa, Florida, 0 per cent (N = 102). Contrary to expectations, there was no corresponding difference in reported lifetime needle sharing experiences, which ranged from 70 per cent in New York to 99 per cent in San Antonio. HIV seropositivity was associated only with geographic location and ethnicity; however, because needle sharing is practiced by parenteral drug abusers in areas where seroprevalence is still relatively low, these areas are potentially vulnerable to the same catastrophic spread seen in the Northeast. A window of opportunity exists where prompt, vigorous, and aggressive efforts at prevention could have major impact.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bakeman R., Lumb J. R., Jackson R. E., Smith D. W. AIDS risk-group profiles in whites and members of minority groups. N Engl J Med. 1986 Jul 17;315(3):191–192. doi: 10.1056/NEJM198607173150312. [DOI] [PubMed] [Google Scholar]
- Black J. L., Dolan M. P., DeFord H. A., Rubenstein J. A., Penk W. E., Robinowitz R., Skinner J. R. Sharing of needles among users of intravenous drugs. N Engl J Med. 1986 Feb 13;314(7):446–447. doi: 10.1056/nejm198602133140712. [DOI] [PubMed] [Google Scholar]
- Chaisson R. E., Moss A. R., Onishi R., Osmond D., Carlson J. R. Human immunodeficiency virus infection in heterosexual intravenous drug users in San Francisco. Am J Public Health. 1987 Feb;77(2):169–172. doi: 10.2105/ajph.77.2.169. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Drucker E. AIDS and addiction in New York City. Am J Drug Alcohol Abuse. 1986;12(1-2):165–181. doi: 10.3109/00952998609083750. [DOI] [PubMed] [Google Scholar]
- Levy N., Carlson J. R., Hinrichs S., Lerche N., Schenker M., Gardner M. B. The prevalence of HTLV-III/LAV antibodies among intravenous drug users attending treatment programs in California: a preliminary report. N Engl J Med. 1986 Feb 13;314(7):446–446. doi: 10.1056/NEJM198602133140711. [DOI] [PubMed] [Google Scholar]
- Maayan S., Wormser G. P., Hewlett D., Miller S. N., Duncanson F. P., Rodriguez A., Perla E. N., Koppel B., Rieber E. E. Acquired immunodeficiency syndrome (AIDS) in an economically disadvantaged population. Arch Intern Med. 1985 Sep;145(9):1607–1612. [PubMed] [Google Scholar]
- Marmor M., Des Jarlais D. C., Friedman S. R., Lyden M., el-Sadr W. The epidemic of acquired immunodeficiency syndrome (AIDS) and suggestions for its control in drug abusers. J Subst Abuse Treat. 1984;1(4):237–247. doi: 10.1016/0740-5472(84)90002-3. [DOI] [PubMed] [Google Scholar]
- Ragni M. V., Lewis J. H., Bracken M., Toth R., Stokes J., Steffensen D. O. Detection of acquired immunodeficiency syndrome (AIDS) retrovirus antibody by lymphadenopathy-associated virus (LAV) enzyme immunoassay in low- and high-risk populations. Transfusion. 1986 May-Jun;26(3):299–301. doi: 10.1046/j.1537-2995.1986.26386209394.x. [DOI] [PubMed] [Google Scholar]
- Robert-Guroff M., Weiss S. H., Giron J. A., Jennings A. M., Ginzburg H. M., Margolis I. B., Blattner W. A., Gallo R. C. Prevalence of antibodies to HTLV-I, -II, and -III in intravenous drug abusers from an AIDS endemic region. JAMA. 1986 Jun 13;255(22):3133–3137. [PubMed] [Google Scholar]